Glycopyrronium

證據等級: L5

預測適應症: 10 個

Glycopyrronium: From Anticholinergic (Antimuscarinic) Therapy to Irritable Bowel Syndrome

One-Sentence Summary

Glycopyrronium is a peripheral antimuscarinic (anticholinergic) agent; this evidence pack does not record its originally licensed indication(s) or detailed mechanism of action data (data gap). The TxGNN model predicts it may be effective for Irritable Bowel Syndrome (IBS), but this is currently supported by 0 clinical trials and only 1 indirectly related preclinical publication — the evidence base is very thin.

Quick Overview

Item	Content
Original Indication	Not documented in this evidence pack (no ARTG license records available)
Predicted New Indication	Irritable Bowel Syndrome
TxGNN Prediction Score	98.84%
Evidence Level	L4 (preclinical / mechanistic only)
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data for glycopyrronium is not available in this evidence pack. Based on pharmacological information referenced within the evidence base itself, glycopyrronium is a peripheral antimuscarinic agent that antagonises M3 muscarinic receptors — the same receptor class targeted by established GI antispasmodics such as dicyclomine and hyoscyamine, and by long-acting muscarinic antagonists (e.g. tiotropium) used in respiratory disease.

Mechanistically, M3-receptor blockade can reduce intestinal smooth-muscle contraction and, in theory, visceral hypersensitivity — both relevant to IBS symptom control. Antispasmodics as a drug class are an accepted, guideline-recognised treatment option for IBS, which lends class-level plausibility to this prediction.

However, this plausibility is at the drug-class level, not drug-specific. The single supporting publication in this evidence pack (PMID 9696463) actually studies tricyclic antidepressants’ effects on rat colonic afferent nerves — it does not test glycopyrronium directly. No clinical trials, case series, or glycopyrronium-specific preclinical GI motility studies are currently available to support this indication.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
9696463	1998	Preclinical (animal)	Pain	Examined effects of tricyclic antidepressants (imipramine, desipramine, clomipramine) on mechanosensitive pelvic nerve afferents in the rat colon; relevant to visceral sensitivity mechanisms but does not test glycopyrronium itself

Australia Market Information

No ARTG entries currently registered — glycopyrronium is not marketed in Australia according to this evidence pack.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. This evidence pack could not retrieve key warnings, contraindications, or drug interaction data for glycopyrronium (source lookup returned no result).

Conclusion and Next Steps

Decision: Hold

Rationale:

The IBS prediction rests on class-level mechanistic plausibility only (L4, decision stage S1/”Research Question”), with no clinical trials and only one indirectly relevant preclinical publication (which studies a different drug class, not glycopyrronium).
A blocking data gap exists at the drug level: TGA/PI-level warnings and contraindications could not be retrieved, so a formal safety pre-assessment cannot be completed.

To proceed, the following is needed:

TGA-approved Product Information (warnings, contraindications, drug interactions) for glycopyrronium
Confirmed mechanism of action and original approved indication(s)
Glycopyrronium-specific preclinical or clinical data on GI motility/visceral sensitivity relevant to IBS
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.